Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Corporate Governance

Overview

Our commitment to scientific excellence, operational efficiency, and customer focus positions us as a preferred partner in the industry. In this section, we highlight how Sai Life Sciences drives growth through strategic investments in infrastructure, technology and talent, all aimed at delivering value to our stakeholders.

Financial Information
Annual Reports
Corporate Governance
Shareholder Service
Disclosures

Corporate Governance

Dr. K. Ranga Raju

Chairman

Krishna Kanumuri

Managing Director and CEO

Siva Chittor

Whole-Time Director & Chief Financial Officer

Ramesh G Iyer

Independent Director

Suchita Sharma

Independent Director

Dr. Dinesh V Patel

Independent Director

Siva Chittor

Whole-Time Director & Chief Financial Officer

Runa Karan

Company Secretary, Compliance Officer & Legal Head

Key items

Download

Committees of the board

Download

Key items

Download

CG Report for Quater ended 31.03.2026

Download

CG Report for Quarter ending 31.12.2025

Download

CG Report for Quarter ending 30.09.2025

Download

CG Report for Quarter ending 30.06.2025

Download

CG Report for Quarter ending 31.03.2025

Download

CG Report for Quarter ending 31.12.2024

Download

Key items

Download

Basis of Allotment (BoA) AD

Download

Prospectus

Download

Red Herring Prospectus

Download

Draft Red Herring Prospectus

Download

Frost & Sullivan Industry Report

Download

Corporate Governance Policies/Documents

Key items

Download

Dividend Distribution Policy

Download

Familiarisation Programme for ID-FY26

Download

Management ESOP Scheme 2018

Download

ESOP Scheme 2008

Download

Criteria for Making Payments to Non-Executive Directors

Download

Anti-Sexual Harassment Policy

Download

Archival Policy

Download

Code of Conduct for BoD and SMPs

Download

Code of conduct for NEDs

Download

Corporate Social Responsibility Policy

Download

Determining Material Subsidiaries

Download

Disclosure of Contact details of KMP as per Reg 30(5)

Download

Familiarisation Programme for Id

Download

Nomination and Remuneration Policy

Download

Policy for Evaluation of Performance of BoD

Download

Policy for Familiarisation Programme for ID

Download

Policy for Preservation of Documents

Download

Policy for Determination of Materiality

Download

Policy on Related Party Transactions

Download

Policy to Promote Diversity of Board of Directors

Download

Risk Management Policy

Download

Code of Practices-Fair Disclosure of UPSI

Download

Insider Trading Policy

Download

Succession Policy

Download

Terms and Conditions for appointment of Independent Director

Download

UPSI Leak Inquiry Policy

Download

Whistle Blower Policy

Download

Material Contracts

Key items

Download

Offer Agreement

Download

Amendment to Offer Agreement

Download

Registrar Agreement

Download

Amendment to Registrar Agreement

Download

Monitoring Agency Agreement

Download

Cash Escrow and Sponsor Banks Agreement

Download

Share Escrow Agreement

Download

Syndicate Agreement

Download

Material Documents

Key items

Download

Certificate of Commencement for Business

Download

Annual Reports of the Company for Fiscal year 2022

Download

Annual Reports of the Company for Fiscal year 2023

Download

Annual Reports of the Company for Fiscal year 2024

Download

Agreement dated November 27, 2023 along-with amendment agreement dated July 10, 2024

Download

BR taking on record the approval for OFS by each of selling shareholders

Download

BR Approving RHP

Download

Tripartite agreement between Company, NSDL and Registrar of the Offer

Download

BR Approving the Offer and Related Matters

Download

Tripartite agreement between Company, CDSL and Registrar of the Offer

Download

Certificate of Incorporation

Download

Vishvakarma Consultancy Services Consent Letter

Download

Consent letters and authorisations from selling shareholders

Download

Consents by Directors, Company Secretary, Compliance Officer and Legal Head, legal counsels to the Company, Bankers to the Company, Banker(s) to the Offer, the BRLMs, Syndicate Members, Registrar to the offer to act in respective capacities

Download

Deloitte Consent Letter

Download

Due diligence certificate dated July 24, 2024

Download

BR Approving DRHP

Download

Frost & Sullivan consent

Download

Gift Deed along-with supplementary letter

Download

In-principle listing approvals by NSE and BSE

Download

Frost & Sullivan report

Download

Loan utilization certificate

Download

Certified Copies of MoA and AoA

Download

BR and SR for approval of revised remuneration structure of Chairman and WTD

Download

Certificate by Bashetty & Joshi certifying Basis for Offer price

Download

Certificate by Bashetty & Joshi certifying details of Employee Stock options scheme

Download

Certificate by Bashetty & Joshi certifying details of outstanding borrowings

Download

Certificate by Bashetty & Joshi certifying KPIs

Download

Certificate by Bashetty & Joshi certifying dues owed to material creditors, MSME enterprises and other creditors

Download

Certificate by Bashetty & Joshi certifying weighted average cost of acquisition

Download

Examination Report

Download

Statement of Possible Special Tax Benefits certificate

Download

Scheme of arrangement between Company, Sai Quest Syn and their respective shareholders and creditors along-with Valuation report

Download

SEBI Final observation letter

Download

Shareholders’ agreement dated March 27, 2019 along-with amendment agreement dated July 4, 2024

Download

SR Approving Fresh Issue and Other Related Matters

Download

IPO committee resolution taking on record consent to participate in OFS by each of selling shareholders

Download

Audit committee resolution approving KPIs for disclosure

Download

BR and SR for approval of revised remuneration structure of MD and CEO

Download

Compliance

Key items

Download

EPFO Form 5A

Download

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Corporate Policies
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube

Disclaimer

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the draft red herring prospectus dated July 12, 2024 (“DRHP”) of Sai Life Sciences Limited (the “Company”) filed with Securities and Exchange Board of India (“SEBI“), BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”, and together with BSE, the “Stock Exchanges”) hosted on this website in connection with the proposed initial public offering of equity shares of the Company (the “Offer“) in consultation with Kotak Mahindra Capital Company Limited, IIFL Securities Limited, Jefferies India Private Limited and Morgan Stanley India Company Private Limited (“BRLMs”) or any of their affiliates, or their respective directors, officers and employees (together, the “Affiliates“) . The DRHP has been made available on this website in electronic form as prescribed under Regulation 26 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the DRHP. By accessing the DRHP, you agree to follow the following terms and conditions, including any modifications to them from time to time.

The contents of the DRHP are for your information only and you acknowledge that access to the DRHP is intended for use by you only and you agree not to forward the DRHP on to any other person, internal or external to your company, in whole or in part, or otherwise provide access via e-mail or otherwise to any person. No part of the contents herein shall be copied or duplicated in any form by any means or redistributed and in particular, may not be forwarded to any person in the United States or to any U.S. address. Any forwarding, distribution or reproduction of the contents herein in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the applicable laws of other jurisdictions. The Company, BRLMs and/or their Affiliates are not soliciting any action based on it, and it should not be construed as an offer to sell or the solicitation of any offer to buy or subscribe for any security and should not be construed as such. The DRHP does not amount to, or is intended to be, a prospectus or an offer document, in terms of the Companies Act, 2013, and the SEBI ICDR Regulations, and nothing in the DRHP constitutes an offer or an invitation by or on behalf of either the Company or any of the members of the syndicate to subscribe for or purchase any of the securities described therein. Neither the Company, the BRLMs nor their respective affiliates represent that the contents of the DRHP herein are accurate or complete. The information contained herein not been updated since its original publication date and may not reflect the latest updates.

The information in this section is directed at, and is intended for distribution to, and use by, residents of India only. Residents of countries other than India are not authorized to view or use the information in this section. Please note that because of restrictions imposed by law on soliciting securities business in various jurisdictions, subscription to the Offer will not be permitted to residents of certain jurisdictions. The DRHP is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company, BRLMs or any of their Affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements.

The information contained in this portion of our website is not intended to be, and should not be, viewed by U.S. persons (as defined in Regulation S of the Securities Act of 1933, as amended (the “Securities Act”)) or any person in the United States. By accessing such information, you are hereby deemed to represent that (a) you are not a U.S. person and (b) you are not in the United States. The information contained in this website does not constitute an offer for sale in the United States.

The securities offered in the Offer have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such securities are being offered and sold (i) in the United States to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act (“Rule 144A“) and referred to in the DRHP as “U.S. QIBs“; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the DRHP as “QIBs“) in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act, and (ii) outside the United States in “offshore transactions”, as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made.

The Company has taken all necessary steps to ensure that the contents of the DRHP as appearing on this website are identical to the DRHP filed with SEBI and the Stock Exchanges. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently neither the Company nor its directors, officers and employees, or its affiliates, accept any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data. Neither the Company, the BRLMs nor any of their affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website.

Any person into whose possession the DRHP comes is required to inform himself or herself about and to observe any such restrictions. The Company is not soliciting any action based on the DRHP, and it should not be construed as an offer to sell or the solicitation of an offer to buy any securities by the Company, the selling shareholders, or any of the BRLMs. Potential investors should not rely on the DRHP for any investment decision. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see “Risk Factors” of the red herring prospectus, which may be filed with the Registrar of Companies, Telangana at Hyderabad (“RoC”) in the future. Any decision on whether to invest in the Equity Shares described in the DRHP may only be made after a red herring prospectus has been filed with the RoC and must be made solely on the basis of such red herring prospectus as there may be material changes in the red herring prospectus versus the DRHP. Invitations to subscribe to or purchase the equity shares in the Offer will be made only pursuant to the red herring prospectus if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the red herring prospectus and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid for equity shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India. For details, potential investors should refer to the red herring prospectus, including the section titled “Risk Factors”, when available.

The Company and the BRLMs cannot and does not guarantee the accuracy, timeliness or completeness of the information being made available to you in the DRHP beyond the date of the DRHP. Neither the Company, the BRLMs, nor any of their affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in producing or hosting this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access or use of the website or these materials.

Please note that application forms downloaded and used for subscription to the Offer in contravention of the above will be rejected with no recourse to the BRLMs or the Company or any of their respective affiliates.

If you are not permitted to view these materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Please be advised that to view information on this site, you must accept the conditions of the legal disclaimer.

I hereby confirm that,
I am a Resident of India.
have read the Legal Disclaimer.

I confirm
I do not confirm